Cost of treatment of peripheral neuropathic pain with pregabalin or gabapentin in routine clinical practice: impact of their loss of exclusivity.

It should be noted that differences in average costs per patient observed in the whole sample were maintained in all subgroups, such that the patients on treatment with pregabalin were associated with lower both total and health care costs, except for subgroups of painful diabetic neuropathy and painful mononeuropathies whose differences did not reach statistical significance because of the small sample size of these subgroups (Table 6 ). 4.

also in 111,027 other papers